accelerated approval
An FDA pathway approving a drug for a serious disease based on limited or single-arm data, with the company promising a confirmatory controlled trial later.
As defined in Vincent Rajkumar on the High Price of Cancer Drugs
Where it comes up · 3
- Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]3 claims
- Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant2 claims
- Vincent Rajkumar on the High Price of Cancer Drugs1 claim
Most important claims · 6 of 6Search all claims for “accelerated approval” →
- The accelerated approval pathway grew out of FDA speedups for AIDS drugs such as AZT and ddI during the epidemic, after activists argued that patients facing death should be allowed to try promising drugs, and those early drugs were not especially effective but established a pathway.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]
- Because cancers and rare genetic diseases have high unmet need and lower evidence requirements for accelerated approval, companies invest disproportionately there, bypassing large Phase III trials that are needed in conditions with established standards of care like diabetes.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]
- After accelerated approval on flimsy evidence, regulators should be far more stringent in forcing companies to run and report confirmatory trials and to remove drugs from market when they fail, because companies drag their heels on confirmatory studies.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]
- There are two ways to speed drugs to market: streamlining trials to accrue more patients per unit time, which is genuine speed, or lowering the evidence hurdle for approval, which is not just speed but added uncertainty—approving a drug that may or may not work—and empirical work suggests lowering the bar does not actually improve speed as much as assumed because of the technical nature of surrogate endpoints.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- It would be acceptable to allow uncertainty at market entry in exchange for speed if that uncertainty were later resolved and ineffective drugs were withdrawn, but the FDA almost never removes drugs from the market and has a poor track record of ensuring post-market confirmatory studies get done; when they are done, 20% of the time the drug is converted to full approval on the same surrogate endpoint, which doubles down on the uncertainty rather than eliminating it.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- The FDA is more liberal than European authorities in approving drugs, willing to grant accelerated approval based on smaller single-arm studies for life-threatening diseases—approving a drug that helped 30 of 200 patients with no good alternative while the company promises a controlled trial later—so myeloma drugs reached the U.S. years before the rest of the world, which is good for patients.Vincent Rajkumar on the High Price of Cancer Drugs